

PC28117A

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/776,337
		Filing Date	February 12, 2004
		First Named Inventor	Changquan Sun
		Art Unit	1626
		Examiner Name	Andrew B. Freistein M. BARKER
Sheet 2 of 2	Attorney Docket Number	PC28117A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MB/		C. A. LONDON, "Kinase Inhibitors in the Treatment of Canine Cancer". Proceedings of Annual Canine Cancer Conference, 2002.	
↓		C. A. LONDON, "Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosin Kinase Inhibitor, in Dogs with Spontaneous Malignancies," Clinical Cancer Research, Vol. 9, pp. 2755-2768, 2003.	
		YONGSHENG MA, et al., "Clustering of activating mutations in c-KIT's Juxtamembrane Coding Region in Canine Mast Cell Neoplasms," J Invest Dermatol 1999, pp. 165-170.	
↓		YONGSHENG MA, et al., "Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells," J Invest Dermatol 2000, pp. 392-394.	
/MB/		N.K. PRYER et al, "Proof of Target for SU11654: Inhibition OF KIT Phosphorylation in Canine Mast Cell Tumors", Clinical Cancer Research, Vol., 9, pp. 5729-5734, 2003.	

Examiner Signature	/Michael Barker/	Date Considered	12/15/2007
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.